CN1813875A - External-use medicine for treating leucoderma and its preparing method - Google Patents
External-use medicine for treating leucoderma and its preparing method Download PDFInfo
- Publication number
- CN1813875A CN1813875A CN 200510134616 CN200510134616A CN1813875A CN 1813875 A CN1813875 A CN 1813875A CN 200510134616 CN200510134616 CN 200510134616 CN 200510134616 A CN200510134616 A CN 200510134616A CN 1813875 A CN1813875 A CN 1813875A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- treatment
- external used
- medicine
- used medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a medicine for external application for effectively curing leukoderma and its preparation method. Said medicine is made up by using alcohol, salicylic acid, blue vitriol, ferrous sulfate and sophora flower bud through the processes of soaking, filtration and refinement.
Description
Technical field
The present invention relates to treat external use medicine for treating dermatosis thing field, particularly relate to a kind of treatment vitiligo external used medicine and manufacture method thereof.
Background technology
Vitiligo is a kind of common skin disease, and is commonplace, and it is wide to distribute, and sickness rate accounts for world population about 7/1000ths, and sickness rate is on the rise in recent years, is the difficult pertinacious disease of a kind of department of dermatologry of generally acknowledging both at home and abroad.Though current this sick method of treatment and medicine are a lot, can not reach desirable curative effect, for example, Therapeutic Method such as " ultraviolet therapy ", " BAIDIANJING " medicine, not only weak curative effect, slow, the shortcoming such as the treatment phase is long that takes effect, and also have in various degree side effect.
Summary of the invention
The objective of the invention is to overcome above-mentioned weak point, provide a kind of and study intensively exploitation and long-term clinical practice for many years and the new prescription " white king disappears " that obtains through the inventor, it has, and instant effect, treatment phase are short, effective percentage and cure rate height, easy to use, have no side effect, treatment vitiligo external used medicine and manufacture method thereof that practical value is high.
A kind of treatment vitiligo external used medicine provided by the invention (white king disappears), extracted, filter and make through soaking by following medicine material weight portion proportioning:
Ethanol 15-60 salicylic acid 0.2-4 Chalcanthitum 1-6
Ferrous sulfate 2-12 Flos Sophorae Immaturus 2-20.
In treatment vitiligo external used medicine provided by the invention, preferred medicine material weight portion proportioning is:
Ethanol 15-33 salicylic acid 0.2-1.2 Chalcanthitum 1-4
Ferrous sulfate 2-7 Flos Sophorae Immaturus 2-12.
More preferably medicine material weight portion proportioning is:
Ethanol 30 salicylic acid 1 Chalcanthitum 3
Ferrous sulfate 6 Flos Sophorae Immaturus 10.
In treatment vitiligo external used medicine provided by the invention:
Wherein Chalcanthitum (contain the copper sulfate of five water of crystallization, be commonly called as Chalcanthitum), ferrous sulfate increase melanin, strengthen body immunity.The salicylic acid dredge the meridian passage, blood circulation promoting and blood stasis dispelling.Flos Sophorae Immaturus heat-clearing and toxic substances removing.Ethanol induces sweat, draw all medicines return through.
The full side's compatibility of this pharmaceutical formulation is reasonable, impels mutually, refinforces each other, each other a usefulness.Thereby promote to have improved medication effect, shorten therapeutic process.
Treatment vitiligo external used medicine manufacture method provided by the invention comprises the following steps:
(1) soaks extraction
Ethanol 15-60 weight portion, salicylic acid 0.2-4 weight portion, Chalcanthitum 1-6 weight portion, ferrous sulfate 2-12 weight portion, Flos Sophorae Immaturus 2-20 weight portion are packed in the aseptic container such as glass jar, behind the lid tightening seal, be seated in the ventilating and cooling place 10 days to 20 days, and preferred 15 days to 20 days, took out soaking medicated liquid.
(2) filter
Soaking medicated liquid with above-mentioned steps (1) obtains is filtered into pure medicinal liquid under gnotobasis.
(3) fill
The pure medicinal liquid that above-mentioned steps (2) is obtained under gnotobasis fill as in containers such as 5,10,20 milliliters such as plastics or the vial, sealed container port, bottled treatment vitiligo external used medicine, be seated in the ventilating and cooling place and preserve.
In the method according to manufacturing provided by the invention treatment vitiligo external used medicine, described step (1) is soaked and is extracted, and is soaking as the glass jar container of generally adopting of this area, and immersion process also is known communication method using common.Described soak time does not have strict regulations, but unsuitable long or very little.Consider can be thoroughly the pharmaceutical compositions of medicine material to be soaked more fully to extract, generally soaked 10-20 days, be preferably 15-20 days.Filtration, fill all are to use commercially available equipment known in the art described in the described step (2) (3), and its working procedure also is the known conventional method of regulation.
The specific embodiment
The present invention further specifies the present invention with the following example, but protection scope of the present invention is not limited to the following example
Embodiment 1
Ethanol, salicylic acid, Chalcanthitum, ferrous sulfate, the Flos Sophorae Immaturus packed into by listed weight in the table 1 soak in the glass jar, the commercially available filter plant of reuse is maneuver routinely, under gnotobasis, decoction soaking is filtered 7.2 kilograms of clean pure medicinal liquids that obtain, promptly treat the vitiligo external used medicine.
Embodiment 2
Embodiment 2 manufacturing steps are identical with the step of embodiment 1, and different is its medicine material consumption is shown in (embodiment 2) in the table 1, and the clean pure medicinal liquid of the treatment purplish or white patches on the skin wind external used medicine that wherein obtains is 28.8 kilograms.
Embodiment 3
Embodiment 3 manufacturing steps are identical with the step of embodiment 1, and different is its consumption is shown in (embodiment 3) in the table 1, and the clean pure medicinal liquid that wherein obtains is 15.15 kilograms.
Table 1
| Embodiment 1 | Embodiment 2 | Embodiment 3 | |
| Ethanol (kilogram) | 15 | 50 | 30 |
| Salicylic acid (kilogram) | 0.2 | 1.5 | 1 |
| Chalcanthitum (kilogram) | 1 | 4 | 3 |
| Ferrous sulfate (kilogram) | 2 | 7 | 6 |
| The Flos Sophorae Immaturus (kilogram) | 6 | 12 | 10 |
| The clean pure medicinal liquid (kilogram) that obtains | 7.2 | 28.8 | 15.15 |
The clinical observation result of treatment vitiligo external used medicine curative effect provided by the invention is as shown in the table:
Year March March to 2004 calendar year 2001, the whole nation the 69 training disease research institute, Hebei province Dingzhou City vitiligo hospital, three tame hospitals of Hebei province Dingzhou City dermatosis hospital used the treatment vitiligo external used medicine provided by the invention white king that disappears to treat the leucoderma disease clinical observation on the therapeutic effect and be summarized as follows table:
Clinical observation on the therapeutic effect
From year days in March day to 2004 March calendar year 2001 three tame large hospital use the present invention's white king's Drug therapy leucoderma disease 360 examples that disappear
| The case history number | Sex | Number | Each age group (year) | Symptom before going to a doctor | Therapeutic effect | Mean age | The mean treatment fate | |||||
| The initial stage number | Mid-term number | The later stage number | Effective transference cure 36-69% | Produce effects transference cure 70-94% | Cure transference cure 95-99% | Invalid transference cure is below 35% | ||||||
| 72 | The man | 30 | 10-19 | 50 | 12 | 10 | 2 | 4 | 65 | 1 | ||
| The woman | 42 | |||||||||||
| 118 | The man | 50 | 20-29 | 68 | 26 | 24 | 10 | 19 | 86 | 3 | ||
| The woman | 68 | |||||||||||
| 83 | The man | 39 | 30-39 | 33 | 39 | 11 | 12 | 19 | 50 | 2 | ||
| The woman | 44 | |||||||||||
| 38 | The man | 18 | 40-49 | 12 | 10 | 16 | 2 | 8 | 25 | 3 | ||
| The woman | 20 | |||||||||||
| 28 | The man | 12 | 50-59 | 5 | 7 | 16 | 6 | 13 | 6 | 3 | ||
| The woman | 16 | |||||||||||
| 13 | The man | 6 | 60-69 | 1 | 2 | 10 | 3 | 5 | 1 | 4 | ||
| The woman | 7 | |||||||||||
| 8 | The man | 4 | 70-79 | 3 | 5 | 1 | 1 | 6 | ||||
| The woman | 4 | |||||||||||
| The man | 80-89 | |||||||||||
| The woman | ||||||||||||
| Add up to 360 | The man | 159 | 36 | 69 | 233 | 22 | ||||||
| The woman | 201 | |||||||||||
The state of an illness is followed up a case by regular visits to: follow up a case by regular visits to case in 180 days and follow up a case by regular visits to case in 100 360 days and follow up a case by regular visits to case 100 after 160 three years
Curative effect: through the statistical procedures (person in charge of statistics of statistical unit Hebei province Dingzhou City statistics bureau: the king)
Effective percentage is that 93.8% ± 2.6 cure rate is 26.8 years old 64.7% ± 7.5 mean age mean treatment natural law 389.6 days
The efficacy assessment standard of medicine of the present invention is as follows in the table:
(1) effective: transference cure 36-69% is assessed as effectively.
(2) produce effects: transference cure 70-94% is assessed as produce effects.
(3) cure: transference cure 95-99% is assessed as healing.
(4) invalid: it is invalid that transference cure is assessed as below 36%.
Two groups of therapeutic effect observations in Hebei province Dingzhou City vitiligo hospital year March March to 2004 calendar year 2001 and other results are as follows:
(1) two group of using method and medicine are respectively the treatment group and use treatment vitiligo external used medicine provided by the invention " white king disappears ".Wipe once every day, uses according to quantity at every turn.Matched group uses " BAIDIANJING " tincture external used medicine.Wipe once every day, uses according to quantity at every turn.
(2) observe the course of treatment, two groups was to observe 12 courses of treatment continuously a course of treatment with 30 days all.
The clinical efficacy controlled observation
The treatment group:
Hebei province's Dingzhou City vitiligo hospital uses treatment vitiligo external used medicine provided by the invention white king's Drug therapy leucoderma disease 21 examples that disappear from year March day to 2004 March calendar year 2001
| The case history number | Sex | Number | Each age group (year) | Symptom before going to a doctor | Therapeutic effect | Mean age | The mean treatment natural law | |||||
| The initial stage number | Mid-term number | The later stage number | Effective transference cure 36-69% | Produce effects transference cure 70-94% | Cure transference cure 95-99% | Invalid transference cure is below 35% | ||||||
| The man | 10-19 | |||||||||||
| The woman | ||||||||||||
| 21 | The man | 11 | 20-29 | 1 | 3 | 17 | 2 | 4 | 13 | 2 | 26.6 | 186.3 |
| The woman | 10 | |||||||||||
| The man | 30- 39 | |||||||||||
| The woman | ||||||||||||
| Add up to | 2 | 4 | 13 | 186.3 | ||||||||
Effective percentage is that 90.5% ± 2.6 cure rate is 26.6 years old 61.9% ± 7.1 mean age mean treatment natural law 186.3 days
Matched group:
From day to 2004 March calendar year 2001 year Hebei province's Dingzhou City vitiligo hospital use in March BAIDIANJING Drug therapy leucoderma disease 21 examples
| The case history number | Sex | Number | Each age group (year) | Symptom before going to a doctor | Therapeutic effect | Mean age | The mean treatment natural law | |||||
| The initial stage number | Mid-term number | The later stage number | Effective transference cure 36-69% | Produce effects transference cure 70-94% | Cure transference cure 95-99% | Invalid transference cure is below 35% | ||||||
| The man | 10-19 | |||||||||||
| The woman | ||||||||||||
| 21 | The man | 11 | 20-29 | 1 | 3 | 17 | 1 | 3 | 9 | 8 | 26.3 | 268.6 |
| The woman | 10 | |||||||||||
| The man | 30- 39 | |||||||||||
| The woman | ||||||||||||
| Add up to | ||||||||||||
Effective percentage is that 61.9% ± 1.8 cure rate is 26.3 years old 42.8% ± 4.9 mean age mean treatment natural law 268.6 days
It is as follows that Hebei province Dingzhou City vitiligo hospital carries out two groups of comparative results:
Treatment group and matched group are one group of 7 people, 3 groups of each minutes.Case source: successively arrange by patient's prescription on individual diagnosis order, distribute two groups successively.
(1) treatment group: effective percentage is that 90.5% ± 2.6 cure rate is 26.6 years old 61.9% ± 7.1 mean age mean treatment natural law 186.3 days
(2) matched group: effective percentage is that 61.9% ± 1.8 treatment rate is 26.3 years old 42.8% ± 4.9 mean age mean treatment natural law 268.6 days
Treatment is organized in 21 cases: male's 11 examples wherein, and women's 10 examples, the age is at 20-29 between year, 26.6 years old mean age.In matched group 21 cases: male's 11 examples wherein, women's 10 examples, the age is at 20-29 between year, 26.3 years old mean age.
According to male, women and the two groups of mean aves before above two groups of treatments, average period of disease, average disease symptom, by these four analyses before going to a doctor, difference does not have the significance meaning between two groups, and it is more reasonable, balanced to illustrate that grouping is controlled in this examination, has neat same comparability.
Two groups of data contrast efficacy analysis:
The effective percentage of treatment group, cure rate are apparently higher than matched group, and the treatment group treatment phase is short, effect is fast.Two groups of differences all have the significance meaning.Clinical observation shows: treatment group effective percentage is higher than matched group 28.6, and treatment group cure rate is higher than matched group 19.1.The treatment group mean treatment phase was lower than matched group 82.3 days, and the treatment group does not have the side effect of appearance, and matched group has 3 examples side effect to occur.
Treatment vitiligo external used medicine provided by the invention (white king disappears) is observed through three tame hospital clinicals and is summed up, and " white king disappears " external medication leucoderma disease has and consolidates blood circulation promoting and blood stasis dispelling, dredge the meridian passage, the effect of heat-clearing and toxic substances removing, energy is microcirculation improvement fast, enhancing immunity.Promote the skin pigment regeneration function.Its advantage: curative effect is fast, the treatment phase is short, curative effect is high.Have no side effect, easy to use, the medicine valency is cheap, practical value height, social benefit height.
Claims (4)
1, a kind of treatment vitiligo external used medicine is characterized in that being made through soaking, filtering by following medicine material weight portion proportioning:
Ethanol 15-60 salicylic acid 0.2-4 Chalcanthitum 1-6
Ferrous sulfate 2-12 Flos Sophorae Immaturus 2-20.
2,, it is characterized in that described medicine material weight portion proportioning is according to the treatment vitiligo external used medicine of claim 1:
Ethanol 15-33 salicylic acid 0.2-1.2 Chalcanthitum 1-4
Ferrous sulfate 2-7 Flos Sophorae Immaturus 2-12.
3,, it is characterized in that described medicine material weight portion proportioning is according to the treatment vitiligo external used medicine of claim 1:
Ethanol 30 salicylic acid 1 Chalcanthitum 3
Ferrous sulfate 6 Flos Sophorae Immaturus 10.
4, a kind of manufacture method of claim 1 treatment vitiligo external used medicine comprises the following steps:
(1) soaks extraction
Ethanol 15-60 weight portion, salicylic acid 0.2-4 weight portion, Chalcanthitum 1-6 weight portion, ferrous sulfate 2-12 weight portion, Flos Sophorae Immaturus 2-20 weight portion are packed in the aseptic container after the sealing, be seated in ventilating and cooling place 10-20 days, take out soaking medicated liquid;
(2) filter
The soaking medicated liquid that above-mentioned steps (1) is obtained under gnotobasis, filter the pure medicinal liquid of treatment vitiligo external used medicine;
(3) fill
The pure medicinal liquid that above-mentioned steps (2) is obtained carries out fill under gnotobasis packs into and seals in the container, fill treatment vitiligo external used medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101346169A CN100352461C (en) | 2005-12-13 | 2005-12-13 | External-use medicine for treating leucoderma and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101346169A CN100352461C (en) | 2005-12-13 | 2005-12-13 | External-use medicine for treating leucoderma and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1813875A true CN1813875A (en) | 2006-08-09 |
| CN100352461C CN100352461C (en) | 2007-12-05 |
Family
ID=36906307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101346169A Expired - Fee Related CN100352461C (en) | 2005-12-13 | 2005-12-13 | External-use medicine for treating leucoderma and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100352461C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156315A1 (en) * | 2010-12-17 | 2012-06-21 | Keimyung University Industry Academic Cooperation Foundation | Composition for Treating Vitiligo or Canities Comprising Extract from Sophora Japonica as Active Ingredient |
| CN104825647A (en) * | 2015-05-12 | 2015-08-12 | 岑溪市坤发液体燃烧炉具有限公司 | External medicine for treating leucoderma |
-
2005
- 2005-12-13 CN CNB2005101346169A patent/CN100352461C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156315A1 (en) * | 2010-12-17 | 2012-06-21 | Keimyung University Industry Academic Cooperation Foundation | Composition for Treating Vitiligo or Canities Comprising Extract from Sophora Japonica as Active Ingredient |
| US8673371B2 (en) * | 2010-12-17 | 2014-03-18 | Keimyung University Industry Academic Cooperation Foundation | Composition for treating vitiligo or canities comprising extract from sophora japonica as active ingredient |
| CN104825647A (en) * | 2015-05-12 | 2015-08-12 | 岑溪市坤发液体燃烧炉具有限公司 | External medicine for treating leucoderma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100352461C (en) | 2007-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1302793C (en) | Cure-all ointment for treating burns and scald | |
| CN1052420C (en) | Chinese medicine for curing burn and traumatic wound and its production method | |
| CN1813875A (en) | External-use medicine for treating leucoderma and its preparing method | |
| CN1679526A (en) | External-applied medicine for treating achromoderma and production thereof | |
| CN1251736C (en) | Chinese medicinal infusion for treating shingles, parotitis acute mamitis and its manufacturing method | |
| CN103230557B (en) | Beriberi-treating liquid medicine | |
| CN1732978A (en) | Externally applied medicine for treating vitiligo and its preparation process | |
| CN1121870C (en) | Exterior-applied medicine 'Xiaobaiwang' for treating leukoderma and its preparing process | |
| CN1943638A (en) | An External use medicine for treating skin pigment reduction and its preparing method | |
| CN1981815B (en) | Hand and foot antibacterial detergent and its production | |
| CN1251750C (en) | Multifunctional health care fluid for nursing skin | |
| CN1274596A (en) | Compound bee venom liniment and its preparation | |
| CN1169863A (en) | Chinese medicine preparation for sore, ulcer and infection caused by external wound and preparation method | |
| CN1137713C (en) | Chinese medicine oral preparation for curing apoplectic disease-Suyusan and its preparation method | |
| CN102698133A (en) | Traditional Chinese medicine composition for treating verruca plana | |
| CN1294937C (en) | Chinese medicine preparation for treating bromhidrosis | |
| CN1208069C (en) | Process for preparing liquid medicine to treat dermatopathy | |
| CN1067895C (en) | Chinese and Western medicinal preparation for curing hand and foot tinea | |
| CN1251711C (en) | External use anti-inflammatory and myogenic medicine of chinese medicine and its preparing method | |
| CN101077360A (en) | Medicinal composition for treating sugar diabetes skin ulcer and preparation method thereof | |
| CN1098709C (en) | Exterior-applied medicine for treating trichomonas vaginitis and its preparing method | |
| CN1111055C (en) | Ichthyosis treating cream and its preparation | |
| CN1147313C (en) | Orally applied medicine 'Gukangwang' for treating arthropathy and its preparing process | |
| CN100349604C (en) | Medicine for treating skin scald and burn and preparation method thereof | |
| CN1093896A (en) | Tonic cream for foot-xiangye jiezu cream and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071205 Termination date: 20121213 |